£50 million, eight universities, 14 years: the centre trying to cure inflammation rather than control it
What happened
On 23 September 2026, UK Research and Innovation announced a new £50 million research centre aimed at chronic inflammatory diseases. It is funded by the Medical Research Council and led by the University of Birmingham. Its full name is the MRC Centre of Research Excellence in Restorative Immunology. The money is committed over 14 years, which is unusually long for research funding. Most grants run for three to five years. The centre brings together researchers from eight universities: Birmingham, Newcastle, University College London, Bristol, Cambridge, Glasgow, Oxford and Kyoto University in Japan. The conditions it will study include inflammatory arthritis, inflammatory bowel disease, autoimmune liver disease and Sjögren's disease. These affect both children and adults. The aim is stated plainly in the centre's name. "Restorative" means putting something back to how it should be. The team wants to understand why the immune system starts attacking the body in the first place, and - this is the harder part - why the inflammation keeps going in some people and settles down in others. From there, they want to build treatments that address the underlying cause rather than simply keeping symptoms under control. The centre will also include patient research partners, meaning people who live with these conditions will be involved in shaping the work rather than just being studied.
Why this matters
If you have never had one of these conditions, it can be hard to picture what living with them is like. Inflammatory arthritis can make it painful to open a jar or climb stairs. Inflammatory bowel disease can mean planning every journey around where the toilets are. Sjögren's disease can dry out eyes and mouth so badly that talking becomes uncomfortable. These are not minor inconveniences. They shape daily life. Most current treatments are good at damping inflammation down. Many people do very well on them. But they usually need to be taken for years, sometimes for life, and they often come with side effects or regular monitoring. They control the fire rather than putting it out. That is the gap this centre is aiming at. There is also a practical reason the 14-year timescale matters. Chronic diseases are slow. Understanding why inflammation persists in one person and not another needs long follow-up, and researchers cannot do that on a three-year grant. Committing money for 14 years lets a team plan properly. And the scale tells you something. Eight universities across two continents do not join a project like this lightly. That is a strong signal from the UK research community about where they think progress is possible.
What the evidence actually says
It is important to be honest about what has and has not happened here. What has happened is that money has been committed and a team has been assembled. That is a beginning, not a result. No new treatment has been discovered. No trial has reported. Nobody with arthritis or Crohn's disease should change anything they are doing because of this announcement. The scientific idea behind the centre is well founded, though. Inflammation is a normal and useful process - it is how your body responds to injury and infection. The problem in these diseases is that it does not switch off. Researchers already know that some people's inflammation resolves and others' does not, and they do not fully understand why. MRC describes chronic inflammatory diseases as placing a major burden on patients, health services and the economy. That framing is part of why the investment was made. The centre's stated approach is to work out why immune-mediated diseases develop, why inflammation persists in some people, and then use that knowledge to develop therapies that address underlying causes rather than only controlling symptoms. Whether that works is genuinely unknown. Plenty of well-funded research programmes do not deliver the treatment they hoped for. What a 14-year commitment buys is the time to find out properly.
Practical advice
If you live with an inflammatory condition, here is what is actually useful today. Keep taking your current medicines exactly as prescribed. A research announcement is not a reason to change anything. Stopping or reducing an immune medicine without medical advice can cause a flare, and flares can do lasting damage. If your condition is not well controlled, that is worth raising with your specialist team now rather than waiting for future research. Treatments have improved considerably in the last decade and there may be options you have not tried. If you are interested in taking part in research, you can register your interest through the NHS Be Part of Research service. Many inflammatory disease studies specifically want people who are already living with the condition, and patient involvement is written into this centre's plan. Practical day-to-day things still matter. Taking medicines consistently is one of the strongest predictors of how well these conditions are managed. If remembering doses is hard, speak to your pharmacist - dosette boxes, reminders and repeat arrangements exist for exactly this reason. And be wary of anything online promising to "cure" or "reverse" autoimmune disease through diet alone. Diet can help some people feel better. It is not a substitute for treatment, and the researchers now spending £50 million on this problem would not need to if the answer were that simple.
Qurexa perspective
Long-term inflammatory conditions usually mean long-term medicines, and that is where we see the day-to-day reality of this. The treatments for inflammatory arthritis or bowel disease often involve several medicines, taken on different schedules, with repeat prescriptions that have to keep arriving on time. Miss a few doses during a bad week and a flare can follow. That is the practical gap between a prescription being written and a person actually taking it. Getting medicines delivered reliably, and having support to keep track of them, is a small thing that makes a real difference over years. It is the part of the problem we work on while researchers work on the bigger one. If managing repeat prescriptions for a long-term condition is a struggle in your household, it is worth asking your pharmacy what support exists. Many people do not realise how much is available.
What to know
The Medical Research Council is investing £50 million over 14 years in a new centre led by the University of Birmingham, working with seven other universities including Oxford, Cambridge, Glasgow, Newcastle, UCL, Bristol and Kyoto. The centre will study chronic inflammatory diseases - including inflammatory arthritis, inflammatory bowel disease, autoimmune liver disease and Sjögren's disease - and try to develop treatments that tackle causes rather than symptoms. This is funding and intent, not a breakthrough. Nothing changes for patients today. But the length of the commitment and the number of institutions involved make it a serious effort at a problem that affects a great many people. If your own condition is not well controlled, talk to your specialist team now. That is the change worth making this week. Sources: UK Research and Innovation, 'New £50M research centre targets cures for inflammatory diseases', 23 September 2026, https://www.ukri.org/news/new-50m-research-centre-targets-cures-for-inflammatory-diseases/; University of Birmingham, '£50m funding to find cure rather than control for inflammatory diseases', 2026, https://www.birmingham.ac.uk/news/2026/50m-funding-to-find-cure-rather-than-control-for-inflammatory-diseases; University of Manchester, 'New £50m MRC Centre to study how environmental exposures cause chronic inflammatory diseases', 2026, https://www.manchester.ac.uk/about/news/new-50m-mrc-centre-to-study-how-environmental-exposures-cause-chronic-inflammatory-diseases/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Related articles
Six hours, not never: the ICU filter notice the MHRA issued today
The UK's medicines and devices regulator has issued a new safety notice to hospitals, and it is about timing. On 13 October 2026 the Medicines and Healthcare p…
Eight pages to a minister: what the data guardian says trust is worth
On 12 October 2026, the government published a letter about who should be trusted with NHS patient data. It was written by Dr Nicola Byrne, the National Data G…
Update: the tests came back, and it was not plague
This is a follow-up to a story we covered on 5 October, when nearly 200 people were being monitored after the death of a laboratory worker in Siberia. There has…